Long-term evaluation of the efficacy and safety of Nd:YAG laser vitreolysis for symptomatic vitreous foaters

• Published in: Arquivos brasileiros de oftalmologia Vol. 87; no. 2
• Main Authors: Nunes, Guilherme M., Ludwig, Gustavo D., Gemelli, Henrique, Zanotele, Márgara, Serracarbassa, Pedro D.
• Format: Journal Article
• Language: Portuguese
• Published: Conselho Brasileiro de Oftalmologia 2024
• Subjects: OPHTHALMOLOGY; Vitreoretinal surgery; Doenças oculares; Qualidade de vida; Lasers, solid-state; Vitreous body; Visual acuity; Vitrectomia; Laser therapy; Inquéritos e questionários; Corpo vítreo; Quality of life; Surveys and questionnaires; Terapia a laser; Cirurgia vitreorretiniana; Vitrectomy; Eye diseases; Acuidade visual; Lasers de estado sólido
• ISSN: 1678-2925
• DOI: 10.5935/0004-2749.2021-0395

ABSTRACT Purpose: This study aimed to evaluate the long-term safety and efficacy of neodymium-doped yttrium aluminum garnet (Nd:YAG) vitreolysis for symptomatic vitreous floaters as it remains a controversial procedure due to insufficient robust evidence in the literature for the maintenance of the results and absence of adverse effects. Methods: This is an observational extension to the previously presented prospective, randomized, double-blind clinical trial. Eight of thirteen subjects who underwent vitreolysis with YAG laser returned for a late reevaluation, 18 months after the procedure, to evaluate the efficacy and safety of the procedure. Results: All patients maintained the improvement in symptomatology noted after the procedure, with 25% showing complete improvement and a similar proportion (37.5%) reporting significant or partial improvement. Objective improvement in opacity was similar to that found at 6 months follow-up. The NEI-VFQ 25 quality of life questionnaire showed no statistically significant difference in responses between the 6th and 18th month. No adverse effects were noted on clinical examination or reported by patients. Conclusion: Vitreolysis efficacy observed at 6 months of follow-up was maintained until the eighteenth month, with all patients reporting improvement from the pre-procedure state. No late adverse effects were noted. A larger randomized clinical trial is needed to confirm the safety of the procedure.